Background/Aims: The utility of asialo-α1-acid glycoprotein (AsAGP) for assessing the fibrotic burden is unknown. This study examined the diagnostic performance of the AsAGP level for advanced liver fibrosis or cirrhosis in patients with chronic hepatitis B (CHB) or nonalcoholic fatty liver disease (NAFLD). Methods: From July to December 2018, 48 patients with CHB and 75 with NAFLD were recruited prospectively. Transient elastography was used as the reference standard for liver fibrosis, and the cutoff liver stiffness values were defined as 10.0 kilopascal (kPa) for ≥F3 and 12.0 kPa for F4 in CHB patients, and 9.0 kPa for ≥F3 and 11.8 kPa for F4 in NAFLD patients. Results: To predict stage ≥F3 and F4 fibrosis, the areas under the receiver operating characteristic curves of the AsAGP level in patients with CHB were 0.788 (95% CI 0.647-0.930; p=0.005) and 0.825 (95% CI 0.674-0.976; p=0.004), respectively. The cutoff AsAGP levels in patients with CHB that maximized the sum of the sensitivity and specificity values were 1.31 (sensitivity 100.0%, specificity 52.6%) and 1.55 (sensitivity 75.0%, specificity 80.0%), respectively. In contrast, the AsAGP level was similar regardless of the fibrosis stage in patients with NAFLD (all p>0.05 between the stages). Conclusions: The AsAGP level showed acceptable diagnostic accuracy in predicting advanced liver fibrosis and cirrhosis in patients with CHB but not in those with NAFLD. Further studies will be needed to validate the diagnostic performance of the AsAGP level in patients with NALFD. (Korean J Gastroenterol 2019;74:341-348) 
INTRODUCTION
An accurate assessment of the severity of liver fibrosis in patients with chronic hepatitis B (CHB) is essential not only for predicting the long-term clinical course but also for determining if and when to begin antiviral therapy. The most recent guidelines on the management of CHB propose that the presence of significant fibrosis and detectable HBV DNA 342 김승업 등. Asialo-α1-acid Glycoprotein의 간섬유화 예측력 The Korean Journal of Gastroenterology indicate the need for antiviral therapy because the maintenance of viral suppression can reduce the incidence of liver-related complications, including hepatocellular carcinoma (HCC), in patients with CHB who have significant fibrosis or cirrhosis. [1] [2] [3] Among the categories of nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH) is the most progressive and severe condition. 4 NASH is defined as steatosis in the presence of hepatocyte damage, inflammation, and/or subsequent scarring and a replacement of tissue with type I collagen. In contrast to the benign prognosis of simple steatosis, approximately 10-29% of patients with NASH develop cirrhosis within 10 years, which is often followed by liver-related complications, including HCC. 5 Therefore, similar to CHB, the assessment of fibrosis progression in patients with NAFLD is important for identifying those at high risk and determining the optimal time to commence medical interventions.
Thus far, liver biopsy is the gold standard for assessing liver fibrosis, but it has disadvantages, such as invasiveness, cost, risk of complications, lack of available expert practitioners, and intra/interobserver variability. 6 A recent study reported that the serum asialo-α1-acid glycoprotein (desialylated α1-acid glycoprotein; AsAGP) level is elevated in patients with liver diseases compared to healthy controls. 7 In addition, the AsAGP level showed acceptable diagnostic accuracy for liver cirrhosis and HCC. 8 On the other hand, its ability to predict the fibrotic burden in patients with chronic liver diseases is not known. Therefore, this study examined the diagnostic per- which indicates the presence of fat in the liver after excluding the secondary causes of fat accumulation in the liver, such as significant alcohol consumption. 10 The exclusion criteria were as follows: 1) age <19 years, 2) alcohol ingestion in excess of 40 g/day for >5 years,
3) malignancy, 4) an ALT level >5×the upper limit of normal, 
Recruitment information
Initially, this prospective clinical trial assessed the diag- [13] [14] [15] [16] [17] [18] [19] [20] The results are expressed in kilopascal (kPa). The interquartile range is an index of the intrinsic variability among the LS values and corresponds to the range of LS values encompassing 50% of the valid measurements (i.e., between the 25th and 75th percentiles). The 23 
Measurement of the serum AsAGP level
The serum AsAGP level was measured by an antibody-lectin sandwich immunoassay using an AceGP ® ELISA kit (Diagen Inc., Seoul, Korea), as described previously. 8 
Statistical analyses
The data are expressed as the mean±standard deviation, Values are presented as mean±standard deviation or n (%). AsAGP, asialo-α1-acid glycoprotein; HBV, hepatitis B virus; NAFLD, nonalcoholic fatty liver disease. a One-way analysis of variance test. selected as independent predictors of cirrhosis (F4).
Distributions of the LS-based fibrosis stage and corresponding AsAGP level

Independent predictors of advanced fibrosis and cirrhosis
Diagnostic performance of AsAGP for LS-based advanced fibrosis and cirrhosis
The ability of the AsAGP level to predict LS-based advanced fibrosis and cirrhosis in patients with CHB was next evaluated ( On the other hand, patients with a higher ALT level (>5×up- as the gold standard for assessing the fibrotic burden in this study. Thus, these results should be interpreted cautiously.
In conclusion, the AsAGP level predicted advanced fibrosis or cirrhosis acceptably in Asian patients with CHB but not in those with NAFLD. The proposed optimal cutoff AsAGP level for patients with CHB may have utility as a reference in future research. Further largescale studies will be needed to validate the results.
